Psödo-Kaposi sarkomu klinik ve histopatolojik olarak Kaposi Psödo-Kaposi sarkomu histopatolojik ve klinik olarak anjiomatöz hastal›klarla. Request PDF on ResearchGate | Kaposi sarkomu nedeniyle radyoterapi uygulanan 14 hastanın değerlendirilmesi | Methods: The patients undergoing. English Turkish online dictionary Tureng, translate words and terms with different pronunciation options. kaposi’s sarcoma kaposi sarkomu kaposi’s sarcoma in.
|Published (Last):||5 April 2014|
|PDF File Size:||1.9 Mb|
|ePub File Size:||10.4 Mb|
|Price:||Free* [*Free Regsitration Required]|
Therefore, topical imiquimod, an immune response modifier with antiangiogenic properties able to sarkimu interferon-alpha secretion in situ, could prove a good local treatment for KS skin lesions [ 3 ]. After more than one year of follow-up, the patient was still disease-free. During the first week, the three applications were applied by the patient under supervision then the cream was self-administered for the following applications. SB and BS interpreted the patient data aarkomu the disease history and contributed to the literature research.
Consent Written informed consent was obtained from the patient for the publication of this case. National Center for Biotechnology InformationU.
Kaposi’s sarcoma, a virus-associated neoplasm, can be treated with systemic therapy such interferon or chemotherapy, although a local alternative is possible in localized disease. Concerning the literature, there are only two cases reports of KS treated by imiquimod and one phase II study.
Competing interests The authors have indicated no significant interest with commercial supporters. New look at an old disease. Crit Rev Oncol Hematol. Abstract Kaposi’s sarcoma, a virus-associated neoplasm, can be treated with systemic therapy such interferon or chemotherapy, although a local alternative is possible in kapoosi disease. Published online Sep Received Apr 6; Accepted Aug Adverse events reported with imiquimod treatment include local side effects at the application site, ranging from mild erythema to weeping, crusting, and erosions.
After one year of therapy a complete response was observed and confirmed according to histopathology and immunohistochemistry. The treatment protocol consisted of 3 weekly applications Monday, Thursday, Saturday under occlusion for at least 10 hours between 10 and 12 hours.
Journal List Cases J v.
Systemic side effects are exceptional [ kappsi ]. Med Trop Mars ; Introduction Kaposi’s sarcoma KS is a vascular neoplasm with four clinical subtypes: This article has been cited by other articles in PMC. Conclusion Topical imiquimod seems to be a good local treatment for Kaposi’s sarcoma skin lesions with a good toxicity profile, regimens with daily application may offer best clinical results and should be explored and evaluated concerning the toxicity.
Authors’ contributions SB and BS interpreted the patient data regarding the disease history and contributed to sarkoum literature research. After twenty weeks, the purple maculo-papular lesions cleared complete clinical response.
Kaposi’s sarcoma KS is a vascular neoplasm with four clinical subtypes: All variants have been kaposj to the eighth human herpes virus HHV8 [ 1 ]. Written informed consent was obtained from the patient for the publication of this case. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. Support Center Support Center.
Treatment of genital warts with an immune response modifier imiquimod J Am Acad Dermatol. There were no treatment-related deaths or serious adverse events.
Update on classic Kaposi sarcoma therapy: Furthermore, imiquimod can be applied by the patient. The authors have indicated no significant interest with commercial supporters. The phase II trial was conducted by a French team, and 17 patients were enrolled for classic or endemic KS. Imiquimod for actinic keratosis: Author information Article notes Copyright and License information Disclaimer.
Six months later the patient is still disease free.
For all the patients, there were no clinically meaningful changes from baseline in any of the laboratory test values, physical examinations, or vital sign measurements during the course of the study. Topical imiquimod is a ligand of the toll-like receptors 7 and 8 on dendritic cells, increasing immune responses and showing antiviral and antitumoral activities. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Immunocompetent patients with new and small kapos lesions seem to be ideal patients for treatment by topical imiquimod.
The tolerance was good with no side effects.
Imiquimod cream offers an attractive alternative to locally destructive therapies, with less risk of pain, ulceration, and residual scarring. J Am Acad Dermato.